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Efficiency of Antibodies Directed Against Adhesion Molecules to 
Prolong Skin Graft Survival in Mice
Y. van Kooyk, A. de Vries-van der Zwan, L.P. de Waal, and C.G. Figdor
T HE interest to use monoclonal antibodies (MAbs) as 
immunosuppressive agents in allograft rejection 
treatment has increased considerably. Certain MAbs can 
block or modify critical steps in the rejection response and 
have the capacity to prolong graft survival, without the 
appearance of toxic side effects. We have studied the 
potential capacity of anti-adhesion molecules MAbs to 
inhibit the rejection of skin grafts in mice. This study 
focuses on the adhesion molecules that are expressed on 
leukocytes and mediate distinct adhesion interactions be­
tween leukocytes and between leukocytes and endothe­
lium, LFA-1 (CDlla/CD18) is such a leukocyte-specific 
adhesion molecule, which binds its ligand ICAM-1 (CD54), 
present on leukocytes as well as endothelium.1,2 By using 
inhibitory MAbs directed against these adhesion recep­
tors, in vitro studies have demonstrated that this receptor- 
ligand interaction (LFA-1-1CAM-1) is required for anti­
gen-presenting cell (APC)-T-cell interaction, T-B-cell 
interaction, T-cell-mediated killing, as well as T-cell mi­
gration.3 Recently also other ligands of LFA-1 have been 
identified (ICAM-2 and ICAM-3), which may also contrib­
ute in these distinct LFA-l-mediated cell-cell interac­
tions.4 Apart from LFA-1, another adhesion receptor 
(Mac-1) has been described to bind ICAM-1.5 Mac-1 
(CDI lb/CD 18) is a member of the LFA-1 family (CD 18 
family) expressed by monocytes and granulocytes and is 
involved in inflammatory responses mediated by these 
cells. Apart from ICAM-1 other ligands are recognized by 
Mac-1.6
Here we investigated if MAbs directed against LFA-1, 
Mac-1, ICAM-1, or a combination of these antibodies 
could enhance skin graft survival in mice.
MATERIALS AND METHODS 
Animais
Each group consisted of five male C57BL/6 (H-2b) (B6) recipient 
mice that were transplanted each with two male bml (H-2DbKbml) 
tail skin grafts and one syngeneic skin graft on the upper part of 
the tail. One day before transplantation (day -1 )  mice were 
injected intraperitoneally with 300 jug antibody or a combination 
of 300 fig of each antibody, followed by injections twice a week, 
until the end of the experiment (maximal 80 days).
Antibodies
The rat MAbs M17.4 obtained from the American Type Culture 
Collection (ATCC, Rockville, Md) and H I54.163, kindly provided 
by Dr Pierres,7 were directed against the murine LFA-1 a-chain; 
MAb YN1/1.7.4, obtained from ATCC, was directed against 
murine ICAM-1. The MAbs Ml/70.15, obtained from ATCC, and
5C6, kindly provided by Dr M. Robinson, were directed against 
the murine Mac-1 a-chain.
Cell-mediated lympholysis
CML was performed by culturing B6 spleen cells for 5 days at 
37°C with allogeneic bml irradiated spleen cells in Iscove’s 
medium supplemented with 5% fetal calf serum (FCS). The 
cytotoxic response of the effector cells was tested by their 
capacity to kill 5ICr-labeled bml lip opol y saccharide blasts in a 
51Cr release assay of 4 hours at 37°C. Antibodies were added 
during the effector phase and were used in a final concentration of
10 |itg/mL.
RESULTS
The blocking capacity of different anti-adhesion MAbs in 
adhesion-dependent immunologic processes, such as ef- 
fector-target cell interaction, was investigated in vitro. The 
capacity of two anti-LFA-1 (Ml7.4, H I54.163), two anti- 
Mac-1 (Ml/70.15, 5C6), and one anti-ICAM-1 (YN1/1) 
MAb to block the cytotoxic B6 anti-bml response was 
determined. Both anti-LFA-1 antibodies inhibited the spe­
cific lysis of bml target cells by the B6 effector cells, 
anti-ICAM-1 antibodies inhibited partially, whereas anti- 
Mac-1 did not (Fig 1). The combination of anti-LFA-1 and 
ICAM-1 antibodies completely inhibited cytolysis. All 
antibodies that blocked the cytotoxic T-Iymphocyte (CTL) 
response were also potent inhibitors of the B6 anti-bml 
MLR (mixed lymphocyte reaction, not shown). Although 
Mac-1 antibodies did not inhibit the cytotoxic or prolifer­
ative response of the allogeneic bml-induced B6 response, 
these antibodies inhibited other Mac-1-dependent interac­
tions (not shown).
The in vivo capacity of these antibodies to inhibit skin 
transplant rejection was determined by injecting mice 
intraperitoneally with 300 /xg of each antibody, starting 1 
day before transplantation, followed by injections twice a 
week until the end of experiment. This protocol was 
chosen because 300 jxg yielded high serum levels and 
occupied the adhesion receptors expressed on iympho-
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Fig 1. Inhibition of the B6 anti-bml cytolytic response by anti­
bodies directed against adhesion molecules during target cell 
lysis.
cytes, present in spleen or lymph nodes, for more than 3 
days. No side effects were observed after injection of the 
mice twice a week with any of the MAb used for a period 
of more than 10 weeks. Each B6 mouse was transplanted 
with two allogeneic bml skins and one syngeneic B6 skin. 
Syngeneic skins were not rejected during the experiment. 
In contrast, mice rejected the allogeneic bml skins within 
24 days. Treatment of recipient mice with anti-ICAM-l 
antibodies (YNl/l) did not prolong allograft survival, skins 
were rejected within 30 days (Table 1). Treatment of the 
recipient mice with the anti-Mac-1 antibodies (5C6 or 
Mac-1) enhanced graft survival, however transplants were 
still rejected between days 35 to 40, In contrast, when 
recipient mice were treated with anti-LFA-1 antibodies 
(M17.4 or H I54.163), acceptance of the allogeneic graft 
was observed for more than 80 days. Both anti-LFA-1 
antibodies (M17.4 or H154.163) improved graft accep­
tance, although mice injected with H154.163 showed a 
more stable transplant survival (small SD) compared with 
mice injected with Ml7.4 (large SD). Recipient mice 
treated with a combination of anti-LFA-1 and anti-ICAM-1 
antibodies also showed a prolonged survival of the trans­
plant similar to mice injected with anti-LFA-1 MAb alone. 
When mice were treated with a combination of anti-Mac-1 
and anti-ICAM-1 MAbs no prolongation of the skin sur­
vival was observed, indicating that the partial transplant 
acceptance obtained by anti-Mac-1 alone is inhibited when 
anti-ICAM-1 antibodies are added.
DISCUSSION
We have shown that treatment of mice with M17.4 or 
H154.163 (anti-CDlla) potently and effectively prolong 
survival of bml skin grafts in B6 mice for more than 80 
days. This indicates that LFA-1 plays a central role in
*  '
transplant rejection by mediating several cell-cell interac­
tions, Moreover, the combination of anti-LFA-1 and anti- 
ICAM-1 antibodies did not show any additional effect on 
the survival time of the transplant when compared with 
anti-LFA-1 alone. In contrast to the effect observed with 
anti-LFA-1 MAb alone, no survival of the grafts was found
when mice were treated with YNl/l (anti-ICAM-1). Thus,
• < , »
the finding that anti-LFA-1 blocks graft rejection whereas 
anti-ICAM-1 MAb does not, suggests that inhibition of 
other ligands of LFA-1, that is, ICAM-2 or ICAM-3 may 
be more important than LFA-l-ICAM-1 for survival of the 
transplant. On the other hand other anti-ICAM-1 antibod­
ies may be more effective than the one used in this study.
The fact that anti-ICAMrl MAbs were not potent in 
prolonging graft survival could also be explained by the 
fact that anti-rat antibodies were found in serum after 
injecting mice with anti-ICAM-1, In contrast no anti-rat 
antibodies were observed in mice that were injected with 
anti-LFA-1 antibodies alone, because anti-LFA-1 blocked 
the antibody response by B cells. The mechanism by 
which immunosuppression is achieved through anti-LFA-1 
is not known. LFA-1 plays an important role in the homing 
of lymphocytes through binding ICAM-1, or -2, thus an 
altered cell migration may be one mechanism by which 
allograft survival is prolonged. On the other hand the 
LFA-l-ICAM-3 interaction has been suggested to play an 
essential role in the induction of an immune response, and 
thus may be an important step to induce transplant rejec­
tion.
Our findings are in line with the recent observation of 
Nakakura et al8 who demonstrated that the same anti- 
LFA-1 antibody (Ml7.4) results in a prolonged heart 
allograft survival in mice. We have also observed that no 
tolerance was induced in the treated mice, allogeneic skins
Table 1. Survival in Days of Skin Allografts (H-2DbKbm1) Transplanted on B6 (C57BI/6; H-2DbKb) Mice
Antigen MAbs No Survival d
ICAM-1
MAC-1
MAC-1
LFA-1
LFA-1
LFA-1 + ICAM-1 
MAC-1 + ICAM-1
None
YN1/1
M1/70.15
5C6
M17.4
H154.163
M17.4 +YN1/1
M1/70.15 + YN1/1
5
5
5
5
5
5
5
5
22, 22, 
22, 24, 
26, 30, 
26, 32, 
24, 30, 
44, 80, 
20, 28, 
16, 22,
24, 26, 28 
24, 28, 50 
42, 42, 62 
35, 38, 45 
66, 72, 192 
80, 98, 98 
48, 99, 184 
22, 24, 54
Mean Survival 
d ± SD
24.4 ± 2.6
29.6 ± 11.6
40.4 ± 14.0 
35.2 ± 7.0
76.8 ± 67 
80.0 ± 22
75.8 ± 67
27.6 ±11.6
Note. Recipient mice were injected with 300 /ig of each MAb starting 1 d before transplantation, followed by twice a week until the end of experiment (maximal 80 d).
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where ultimately all rejected. This is in contrast to the 
experiments described by Isobe et al (9) who have dem-
»
onstrated that tolerance was induced in mice by a combi­
nation of anti-LFA-1 and anti-ICAM-1 when transplanted 
with allogeneic hearts.
Although anti-Mac-1 antibodies (Mac-1 and 5C6) did not 
inhibit in vitro responses, when injected in vivo a signifi­
cant prolongation of graft survival was observed. How­
ever, a much longer graft survival rate was observed with 
anti-LFA-1. This indicates that Mac-1-dependent adhe-
r  > * *  V
sion of monocytes and granulocytes plays a less important 
role in the process of graft rejection than LFA-1. Because 
a humoral response'was detected in mice injected with
anti-Mac-1 antibodies, the formation of anti-rat antibodies
i  '
could also attribute to the minor affects seen with anti-
*
Mac-1 antibodies.
»
m
In conclusion we have demonstrated that antibodies* >
directed against the adhesion molecules LFA-1, and to a
»
lesser extent, Mac-1 lead to prolonged skin graft survival 
in mice.
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